(11 May 2020) Arbidol – arbidol and Lopinavir/ritonavir combination therapy shows no good

This paper describes retrospective analysis of the clinical data of 178 patients diagnosed as COVID-19 , and divided into 59 patients in the LPV / r group  , 36 cases in the Abidor group, 25 cases in the combined LPV / r and Abidor group, and 58 cases in the conventional treatment group without any antiviral drugs. The main observation endpoint was the time when the new coronavirus nucleic acid of the pharyngeal swab turned negative. There was no statistically significant difference in baseline condition before treatment between patients in LPV / r group, Abidor group, combination group and conventional treatment group. The time for the new coronavirus nucleic acid in the pharyngeal swab to turn negative was (10.20 ± 3.49), (10.11 ± 4.68), (10.86 ± 4.74), (8.44 ± 3.51) d. There was no statistically significant difference between the groups . However, there was a statistically significant difference in the ratio of normal / mild to severe / critically severe on the 7th day in the four groups the combined group (24.0%, 6/25), Abidor group (16.7%, 6/36), LPV / r group (5.4%, 3/56), conventional treatment group (5.2%, 3/58). The frequency of adverse reactions in the three groups of patients using antiviral drugs was significantly higher than that in the conventional treatment group.